A 20-year perspective on the International Fanconi Anemia Registry (IFAR)

David I. Kutler, Bhuvanesh Singh, Jaya Satagopan, Sat Dev Batish, Marianne Berwick, Philip F. Giampietro, Helmut Hanenberg, Arlene D. Auerbach

Research output: Contribution to journalArticle

457 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking agents and cancer predisposition. Recent evidence for the interactions of ataxia-telangiectasia mutated protein ATM and breast cancer susceptibility proteins BRCA1 and BRCA2 (identified as FANCD1) with other known FA proteins suggests that FA proteins have a significant role in DNA repair/recombination and cell cycle control. The International Fanconi Anemia Registry (IFAR), a prospectively collected database of FA patients, allows us the unique opportunity to analyze the natural history of this rare, clinically heterogeneous disorder in a large number of patients. Of the 754 subjects in this study, 601 (80%) experienced the onset of bone marrow failure (BMF), and 173 (23%) had a total of 199 neoplasms. Of these neoplasms, 120 (60%) were hematologic and 79 (40%) were nonhematologic. The risk of developing BMF and hematologic and nonhematologic neoplasms increased with advancing age with a 90%, 33%, and 28% cumulative incidence, respectively, by 40 years of age. Univariate analysis revealed a significantly earlier onset of BMF and poorer survival for complementation group C compared with groups A and G; however, there was no significant difference in the time to hematologic or nonhematologic neoplasm development between these groups. Multivariate analysis of overall survival time shows that FANCC mutations (P = .007) and hematopoietic stem cell transplantation (P = <.0001) define a poor-risk subgroup. The results of this study of patients registered in the IFAR over a 20-year period provide information that will enable better prediction of outcome and aid clinicians with decisions regarding major therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)1249-1256
Number of pages8
JournalBlood
Volume101
Issue number4
DOIs
StatePublished - Feb 15 2003
Externally publishedYes

Fingerprint

Fanconi Anemia
Internationality
Fanconi Anemia Complementation Group Proteins
Registries
Bone
Bone Marrow
BRCA2 Protein
Ataxia Telangiectasia Mutated Proteins
BRCA1 Protein
Neoplasms
DNA
Automatic teller machines
Stem cells
Survival
Hematopoietic Stem Cell Transplantation
Repair
Hematologic Neoplasms
Cell Cycle Checkpoints
Natural History
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Kutler, D. I., Singh, B., Satagopan, J., Batish, S. D., Berwick, M., Giampietro, P. F., ... Auerbach, A. D. (2003). A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood, 101(4), 1249-1256. https://doi.org/10.1182/blood-2002-07-2170

A 20-year perspective on the International Fanconi Anemia Registry (IFAR). / Kutler, David I.; Singh, Bhuvanesh; Satagopan, Jaya; Batish, Sat Dev; Berwick, Marianne; Giampietro, Philip F.; Hanenberg, Helmut; Auerbach, Arlene D.

In: Blood, Vol. 101, No. 4, 15.02.2003, p. 1249-1256.

Research output: Contribution to journalArticle

Kutler, DI, Singh, B, Satagopan, J, Batish, SD, Berwick, M, Giampietro, PF, Hanenberg, H & Auerbach, AD 2003, 'A 20-year perspective on the International Fanconi Anemia Registry (IFAR)', Blood, vol. 101, no. 4, pp. 1249-1256. https://doi.org/10.1182/blood-2002-07-2170
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003 Feb 15;101(4):1249-1256. https://doi.org/10.1182/blood-2002-07-2170
Kutler, David I. ; Singh, Bhuvanesh ; Satagopan, Jaya ; Batish, Sat Dev ; Berwick, Marianne ; Giampietro, Philip F. ; Hanenberg, Helmut ; Auerbach, Arlene D. / A 20-year perspective on the International Fanconi Anemia Registry (IFAR). In: Blood. 2003 ; Vol. 101, No. 4. pp. 1249-1256.
@article{c0c0fdef757e454885cb810dbb9aab5d,
title = "A 20-year perspective on the International Fanconi Anemia Registry (IFAR)",
abstract = "Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking agents and cancer predisposition. Recent evidence for the interactions of ataxia-telangiectasia mutated protein ATM and breast cancer susceptibility proteins BRCA1 and BRCA2 (identified as FANCD1) with other known FA proteins suggests that FA proteins have a significant role in DNA repair/recombination and cell cycle control. The International Fanconi Anemia Registry (IFAR), a prospectively collected database of FA patients, allows us the unique opportunity to analyze the natural history of this rare, clinically heterogeneous disorder in a large number of patients. Of the 754 subjects in this study, 601 (80{\%}) experienced the onset of bone marrow failure (BMF), and 173 (23{\%}) had a total of 199 neoplasms. Of these neoplasms, 120 (60{\%}) were hematologic and 79 (40{\%}) were nonhematologic. The risk of developing BMF and hematologic and nonhematologic neoplasms increased with advancing age with a 90{\%}, 33{\%}, and 28{\%} cumulative incidence, respectively, by 40 years of age. Univariate analysis revealed a significantly earlier onset of BMF and poorer survival for complementation group C compared with groups A and G; however, there was no significant difference in the time to hematologic or nonhematologic neoplasm development between these groups. Multivariate analysis of overall survival time shows that FANCC mutations (P = .007) and hematopoietic stem cell transplantation (P = <.0001) define a poor-risk subgroup. The results of this study of patients registered in the IFAR over a 20-year period provide information that will enable better prediction of outcome and aid clinicians with decisions regarding major therapeutic modalities.",
author = "Kutler, {David I.} and Bhuvanesh Singh and Jaya Satagopan and Batish, {Sat Dev} and Marianne Berwick and Giampietro, {Philip F.} and Helmut Hanenberg and Auerbach, {Arlene D.}",
year = "2003",
month = "2",
day = "15",
doi = "10.1182/blood-2002-07-2170",
language = "English (US)",
volume = "101",
pages = "1249--1256",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - A 20-year perspective on the International Fanconi Anemia Registry (IFAR)

AU - Kutler, David I.

AU - Singh, Bhuvanesh

AU - Satagopan, Jaya

AU - Batish, Sat Dev

AU - Berwick, Marianne

AU - Giampietro, Philip F.

AU - Hanenberg, Helmut

AU - Auerbach, Arlene D.

PY - 2003/2/15

Y1 - 2003/2/15

N2 - Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking agents and cancer predisposition. Recent evidence for the interactions of ataxia-telangiectasia mutated protein ATM and breast cancer susceptibility proteins BRCA1 and BRCA2 (identified as FANCD1) with other known FA proteins suggests that FA proteins have a significant role in DNA repair/recombination and cell cycle control. The International Fanconi Anemia Registry (IFAR), a prospectively collected database of FA patients, allows us the unique opportunity to analyze the natural history of this rare, clinically heterogeneous disorder in a large number of patients. Of the 754 subjects in this study, 601 (80%) experienced the onset of bone marrow failure (BMF), and 173 (23%) had a total of 199 neoplasms. Of these neoplasms, 120 (60%) were hematologic and 79 (40%) were nonhematologic. The risk of developing BMF and hematologic and nonhematologic neoplasms increased with advancing age with a 90%, 33%, and 28% cumulative incidence, respectively, by 40 years of age. Univariate analysis revealed a significantly earlier onset of BMF and poorer survival for complementation group C compared with groups A and G; however, there was no significant difference in the time to hematologic or nonhematologic neoplasm development between these groups. Multivariate analysis of overall survival time shows that FANCC mutations (P = .007) and hematopoietic stem cell transplantation (P = <.0001) define a poor-risk subgroup. The results of this study of patients registered in the IFAR over a 20-year period provide information that will enable better prediction of outcome and aid clinicians with decisions regarding major therapeutic modalities.

AB - Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking agents and cancer predisposition. Recent evidence for the interactions of ataxia-telangiectasia mutated protein ATM and breast cancer susceptibility proteins BRCA1 and BRCA2 (identified as FANCD1) with other known FA proteins suggests that FA proteins have a significant role in DNA repair/recombination and cell cycle control. The International Fanconi Anemia Registry (IFAR), a prospectively collected database of FA patients, allows us the unique opportunity to analyze the natural history of this rare, clinically heterogeneous disorder in a large number of patients. Of the 754 subjects in this study, 601 (80%) experienced the onset of bone marrow failure (BMF), and 173 (23%) had a total of 199 neoplasms. Of these neoplasms, 120 (60%) were hematologic and 79 (40%) were nonhematologic. The risk of developing BMF and hematologic and nonhematologic neoplasms increased with advancing age with a 90%, 33%, and 28% cumulative incidence, respectively, by 40 years of age. Univariate analysis revealed a significantly earlier onset of BMF and poorer survival for complementation group C compared with groups A and G; however, there was no significant difference in the time to hematologic or nonhematologic neoplasm development between these groups. Multivariate analysis of overall survival time shows that FANCC mutations (P = .007) and hematopoietic stem cell transplantation (P = <.0001) define a poor-risk subgroup. The results of this study of patients registered in the IFAR over a 20-year period provide information that will enable better prediction of outcome and aid clinicians with decisions regarding major therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0037441757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037441757&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-07-2170

DO - 10.1182/blood-2002-07-2170

M3 - Article

VL - 101

SP - 1249

EP - 1256

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -